studies

mHNSCC - L2 - all population, pembrolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-040 (all population), 2018 0.80 [0.65; 0.98] 0.80[0.65; 0.98]KEYNOTE-040 (all population), 201810%495NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-040 (all population), 2018 0.96 [0.79; 1.16] 0.96[0.79; 1.16]KEYNOTE-040 (all population), 201810%495NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-040 (all population), 2018 1.52 [0.88; 2.62] 1.52[0.88; 2.62]KEYNOTE-040 (all population), 201810%495NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-040 (all population), 2018 0.33 [0.21; 0.51] 0.33[0.21; 0.51]KEYNOTE-040 (all population), 201810%480NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.15; 0.39] 0.24[0.15; 0.39]KEYNOTE-040 (all population), 201810%480NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57] 1.92[0.35; 10.57]KEYNOTE-040 (all population), 201810%480NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-040 (all population), 2018 1.20 [0.55; 2.62] 1.20[0.55; 2.62]KEYNOTE-040 (all population), 201810%480NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.28 [0.53; 3.10] 1.28[0.53; 3.10]KEYNOTE-040 (all population), 201810%480NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.10 [0.01; 0.81] 0.10[0.01; 0.81]KEYNOTE-040 (all population), 201810%480NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.23 [0.03; 2.12] 0.23[0.03; 2.12]KEYNOTE-040 (all population), 201810%480NAnot evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.04 [0.01; 0.31] 0.04[0.01; 0.31]KEYNOTE-040 (all population), 201810%480NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Cardiac disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Chills TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 3.85 [0.43; 34.71] 3.85[0.43; 34.71]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dyspepsia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33] 3.83[0.17; 85.33]KEYNOTE-040 (all population), 201810%480NAnot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Eye disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57] 1.92[0.35; 10.57]KEYNOTE-040 (all population), 201810%480NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.05 [0.00; 0.79] 0.05[0.00; 0.79]KEYNOTE-040 (all population), 201810%480NAnot evaluable Gastritis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.35 [0.14; 0.86] 0.35[0.14; 0.86]KEYNOTE-040 (all population), 201810%480NAnot evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.57 [0.23; 1.40] 0.57[0.23; 1.40]KEYNOTE-040 (all population), 201810%480NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 2.01 [0.07; 60.26] 2.01[0.07; 60.26]KEYNOTE-040 (all population), 201810%495NAnot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] 0.95[0.06; 15.29]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypertension TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.31 [0.03; 3.04] 0.31[0.03; 3.04]KEYNOTE-040 (all population), 201810%480NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15] 0.16[0.01; 3.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.07 [0.00; 1.17] 0.07[0.00; 1.17]KEYNOTE-040 (all population), 201810%480NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.40 [0.10; 1.57] 0.40[0.10; 1.57]KEYNOTE-040 (all population), 201810%480NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.19 [0.02; 1.61] 0.19[0.02; 1.61]KEYNOTE-040 (all population), 201810%480NAnot evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Nervous system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.04; 5.26] 0.47[0.04; 5.26]KEYNOTE-040 (all population), 201810%480NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.04 [0.01; 0.33] 0.04[0.01; 0.33]KEYNOTE-040 (all population), 201810%480NAnot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15] 0.16[0.01; 3.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] 0.95[0.06; 15.29]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritus generalised TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27] 0.24[0.01; 5.27]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] 0.95[0.06; 15.29]KEYNOTE-040 (all population), 201810%480NAnot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.44 [0.40; 5.16] 1.44[0.40; 5.16]KEYNOTE-040 (all population), 201810%480NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27] 0.24[0.01; 5.27]KEYNOTE-040 (all population), 201810%480NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.54 [0.15; 1.86] 0.54[0.15; 1.86]KEYNOTE-040 (all population), 201810%480NAnot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.31 [0.08; 1.15] 0.31[0.08; 1.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Skin exfoliation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.08 [0.01; 0.65] 0.08[0.01; 0.65]KEYNOTE-040 (all population), 201810%480NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.09 [0.01; 1.72] 0.09[0.01; 1.72]KEYNOTE-040 (all population), 201810%480NAnot evaluable Vascular disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dizziness AE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-02 14:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 101 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons